Temozolomide resistance in glioblastoma multiforme

Moody, 2014, The medicinal chemistry of imidazotetrazine prodrugs, Pharmaceuticals (Basel), 7, 797, 10.3390/ph7070797

Reid, 1997, Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer, Clin Cancer Res, 3, 2393

Middleton, 2000, Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma, J Clin Oncol, 18, 158, 10.1200/JCO.2000.18.1.158

Quirt, 2007, Temozolomide for the treatment of metastatic melanoma: a systematic review, Oncologist, 12, 1114, 10.1634/theoncologist.12-9-1114

Yung, 1999, Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group, J Clin Oncol, 17, 2762, 10.1200/JCO.1999.17.9.2762

Hart, 2013, Temozolomide for high grade glioma, Cochrane Database Syst Rev, 4, CD007415

Newlands, 1992, Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856), Br J Cancer, 65, 287, 10.1038/bjc.1992.57

Cohen, 2005, Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme, Clin Cancer Res, 11, 6767, 10.1158/1078-0432.CCR-05-0722

Alonso, 2007, Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter, Cancer Res, 67, 11499, 10.1158/0008-5472.CAN-07-5312

Baer, 1993, Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells, Br J Cancer, 67, 1299, 10.1038/bjc.1993.241

Bocangel, 2002, Multifaceted resistance of gliomas to temozolomide, Clin Cancer Res, 8, 2725

Kanzawa, 2003, Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide, J Neurosurg, 99, 1047, 10.3171/jns.2003.99.6.1047

Kanzawa, 2003, Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide, Br J Cancer, 89, 922, 10.1038/sj.bjc.6601193

Natsume, 2005, IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide, Cancer Res, 65, 7573, 10.1158/0008-5472.CAN-05-0036

Liu, 2006, Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma, Mol Cancer, 5, 67, 10.1186/1476-4598-5-67

Hermisson, 2006, O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells, J Neurochem, 96, 766, 10.1111/j.1471-4159.2005.03583.x

Uzzaman, 2007, Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells, J Neurosurg, 106, 646, 10.3171/jns.2007.106.4.646

Natsume, 2008, A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation, Cancer Chemother Pharmacol, 61, 653, 10.1007/s00280-007-0520-x

Ujifuku, 2010, miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells, Cancer Lett, 296, 241, 10.1016/j.canlet.2010.04.013

van Nifterik, 2010, Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide, Br J Cancer, 103, 29, 10.1038/sj.bjc.6605712

Goellner, 2011, Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair, Cancer Res, 71, 2308, 10.1158/0008-5472.CAN-10-3213

Lee, 2011, HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A, Int J Cancer, 129, 2104, 10.1002/ijc.25888

Agnihotri, 2012, Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients, J Clin Invest, 122, 253, 10.1172/JCI59334

Ryu, 2012, Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells, J Biomed Biotechnol, 2012, 10.1155/2012/987495

Happold, 2012, Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells, J Neurochem, 122, 444, 10.1111/j.1471-4159.2012.07781.x

Kohsaka, 2012, STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression, Mol Cancer Ther, 11, 1289, 10.1158/1535-7163.MCT-11-0801

Munoz, 2013, Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity, Mol Ther Nucleic Acids, 2, e126, 10.1038/mtna.2013.60

Munoz, 2014, Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43, Cell Death Dis, 5, e1145, 10.1038/cddis.2014.111

St-Coeur, 2015, Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics, J Neurooncol, 125, 91, 10.1007/s11060-015-1899-6

Montaldi, 2015, APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line, Mutat Res Genet Toxicol Environ Mutagen, 793, 19, 10.1016/j.mrgentox.2015.06.001

Chong, 2015, Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status, BMC Cancer, 15, 255, 10.1186/s12885-015-1191-3

Uno, 2011, Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma, Clinics (Sao Paulo), 66, 1747, 10.1590/S1807-59322011001000013

Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 352, 987, 10.1056/NEJMoa043330

Hegi, 2008, Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity, J Clin Oncol, 26, 4189, 10.1200/JCO.2007.11.5964

Blough, 2011, Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma, J Neurooncol, 102, 1, 10.1007/s11060-010-0283-9

Wang, 2004, p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition, Oncogene, 23, 1283, 10.1038/sj.onc.1207244

Koul, 2012, Antitumor activity of NVP-BKM120–a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells, Clin Cancer Res, 18, 184, 10.1158/1078-0432.CCR-11-1558

Nguyen, 2014, Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute totemozolomide resistance independently of MGMT promoter methylation, Clin Cancer Res, 20, 4894, 10.1158/1078-0432.CCR-13-1856

Ma, 2002, Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance, Biochem Pharmacol, 63, 1219, 10.1016/S0006-2952(02)00876-6

Bredel, 2006, Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas, J Clin Oncol, 24, 274, 10.1200/JCO.2005.02.9405

Auger, 2006, Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line, Mol Cancer Ther, 5, 2182, 10.1158/1535-7163.MCT-05-0428

Zhang, 2010, Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications, Oncology, 78, 103, 10.1159/000306139

Oliva, 2010, Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain, J Biol Chem, 285, 39759, 10.1074/jbc.M110.147504

Lee, 2011, Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells, Oncol Lett, 2, 115, 10.3892/ol.2010.210

Ueno, 2015, Augmentation of invadopodia formation in temozolomide-resistant or adopted glioma is regulated by c-Jun terminal kinase-paxillin axis, Biochem Biophys Res Commun, 468, 240, 10.1016/j.bbrc.2015.10.122

Wang, 2015, NF-κB inhibitor reverses temozolomide resistance in human glioma TR/U251 cells, Oncol Lett, 9, 2586, 10.3892/ol.2015.3130

McFaline-Figueroa, 2015, Minor changes in expression of the mismatch repair protein MSH2 exert a major impact on glioblastoma response to temozolomide, Cancer Res, 75, 3127, 10.1158/0008-5472.CAN-14-3616

Banelli, 2015, The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma, Cell Cycle, 14, 3418, 10.1080/15384101.2015.1090063

Giannini, 2005, Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme, Neuro Oncol, 7, 164, 10.1215/S1152851704000821

Clarke, 2009, Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines, Mol Cancer Ther, 8, 407, 10.1158/1535-7163.MCT-08-0854

Kitange, 2009, Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts, Neuro Oncol, 11, 281, 10.1215/15228517-2008-090

Hunn, 2015, Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme, J Neurooncol, 121, 319, 10.1007/s11060-014-1635-7

Quinn, 2009, Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma, J Clin Oncol, 27, 1262, 10.1200/JCO.2008.18.8417

Dresemann, 2010, Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide, J Neurooncol, 96, 393, 10.1007/s11060-009-9976-3